BRPI0918653A2 - combinação de inibidor de ns3 protese de hcv com interferon e ribavirina. - Google Patents

combinação de inibidor de ns3 protese de hcv com interferon e ribavirina.

Info

Publication number: BRPI0918653A2
Authority: BR; Brazil
Prior art keywords: ribavirin; hcv; prosthesis; interferon; inhibitor combination
Prior art date: 2008-09-17

Application number

BRPI0918653A

Other languages

English (en)

Inventor

David Huang

Gerhard Gustav Steinmann

Jerry O Stern

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-09-17

Filing date

2009-09-14

Publication date

2015-12-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41571875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0918653(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-09-14 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2015-12-01 Publication of BRPI0918653A2 publication Critical patent/BRPI0918653A2/pt

Links

102000014150 Interferons Human genes 0.000 title 1
108010050904 Interferons Proteins 0.000 title 1
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
229940079322 interferon Drugs 0.000 title 1
229960000329 ribavirin Drugs 0.000 title 1
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Zoology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BRPI0918653A 2008-09-17 2009-09-14 combinação de inibidor de ns3 protese de hcv com interferon e ribavirina. BRPI0918653A2 (pt)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US9775308P	2008-09-17	2008-09-17
US10903308P	2008-10-28	2008-10-28
US17193509P	2009-04-23	2009-04-23
PCT/US2009/056771 WO2010033443A1 (en)	2008-09-17	2009-09-14	Combination of hcv ns3 protease inhibitor with interferon and ribavirin

Publications (1)

Publication Number	Publication Date
BRPI0918653A2 true BRPI0918653A2 (pt)	2015-12-01

Family

ID=41571875

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0918653A BRPI0918653A2 (pt)	2008-09-17	2009-09-14	combinação de inibidor de ns3 protese de hcv com interferon e ribavirina.

Country Status (24)

Country	Link
US (1)	US8399484B2 (pt)
EP (1)	EP2337583A1 (pt)
JP (1)	JP5539363B2 (pt)
KR (1)	KR20110054003A (pt)
CN (1)	CN102159245B (pt)
AR (1)	AR073516A1 (pt)
AU (1)	AU2009293493B2 (pt)
BR (1)	BRPI0918653A2 (pt)
CA (1)	CA2737376A1 (pt)
CL (1)	CL2011000571A1 (pt)
CO (1)	CO6351753A2 (pt)
EA (1)	EA019965B1 (pt)
EC (1)	ECSP11010877A (pt)
IL (1)	IL210152A0 (pt)
MA (1)	MA32634B1 (pt)
MX (1)	MX2011002602A (pt)
MY (1)	MY152824A (pt)
NZ (1)	NZ591030A (pt)
PE (1)	PE20110343A1 (pt)
TW (1)	TWI454263B (pt)
UA (1)	UA103496C2 (pt)
UY (1)	UY32124A (pt)
WO (1)	WO2010033443A1 (pt)
ZA (1)	ZA201009151B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UY32099A (es)	2008-09-11	2010-04-30	Enanta Pharm Inc	Inhibidores macrocíclicos de serina proteasas de hepatitis c
AU2009293493B2 (en)	2008-09-17	2014-09-18	Boehringer Ingelheim International Gmbh	Combination of HCV NS3 protease inhibitor with interferon and ribavirin
AR075584A1 (es) *	2009-02-27	2011-04-20	Intermune Inc	COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
WO2011038293A1 (en) *	2009-09-28	2011-03-31	Intermune, Inc.	Cyclic peptide inhibitors of hepatitis c virus replication
AU2010313497B2 (en)	2009-10-30	2013-08-01	Boehringer Ingelheim International Gmbh	Dosage regimens for HCV combination therapy comprising BI201335, interferon alpha and ribavirin
MA34547B1 (fr)	2010-09-30	2013-09-02	Boehringer Ingelheim Int	Traitement d'association pour traiter une infection par le vhc
CN103534256B (zh)	2010-12-30	2016-08-10	益安药业	大环丙型肝炎丝氨酸蛋白酶抑制剂
KR20140003521A (ko)	2010-12-30	2014-01-09	이난타 파마슈티칼스, 인코포레이티드	페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제
BR112013017759A2 (pt) *	2011-01-10	2016-10-11	Proteus Digital Health Inc	sistema, método, e artigo para avisar mudança de comportamento
US10201584B1 (en)	2011-05-17	2019-02-12	Abbvie Inc.	Compositions and methods for treating HCV
US8466159B2 (en)	2011-10-21	2013-06-18	Abbvie Inc.	Methods for treating HCV
US8492386B2 (en)	2011-10-21	2013-07-23	Abbvie Inc.	Methods for treating HCV
BR112014006314A2 (pt)	2011-10-21	2017-04-11	Abbvie Inc	métodos para tratamento do vírus da hepatite c (hcv) compreendendo pelo menos dois agentes antivirais de atuação direta, ribavirina, sem interferon
SG2014011670A (en)	2011-10-21	2014-10-30	Abbvie Inc	Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
US20140242029A1 (en) *	2013-02-27	2014-08-28	Boehringer Ingelheim International Gmbh	Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
WO2013137869A1 (en) *	2012-03-14	2013-09-19	Boehringer Ingelheim International Gmbh	Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
WO2013147750A1 (en)	2012-03-27	2013-10-03	Boehringer Ingelheim International Gmbh	Oral combination therapy for treating hcv infection in specific patient sub-population
WO2013147749A1 (en)	2012-03-27	2013-10-03	Boehringer Ingelheim International Gmbh	Oral combination therapy for treating hcv infection in specific patient subgenotype populations
WO2013143581A1 (en)	2012-03-28	2013-10-03	Boehringer Ingelheim International Gmbh	Combination therapy for treating hcv infection in specific patient subgenotype sub-population
WO2014138374A1 (en)	2013-03-08	2014-09-12	Boehringer Ingelheim International Gmbh	Oral combination therapy for treating hcv infection in specific patient sub-population
WO2015103490A1 (en)	2014-01-03	2015-07-09	Abbvie, Inc.	Solid antiviral dosage forms
CN109689063B (zh)	2016-04-28	2026-02-27	埃默里大学	含有炔烃的核苷酸和核苷治疗组合物及其相关用途

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4247479A (en)	1976-12-03	1981-01-27	Hoechst Aktiengesellschaft	Process for the manufacture of aromatic amines from α, β-unsaturated cycloaliphatic ketoximes
US6387365B1 (en)	1995-05-19	2002-05-14	Schering Corporation	Combination therapy for chronic hepatitis C infection
US5908621A (en)	1995-11-02	1999-06-01	Schering Corporation	Polyethylene glycol modified interferon therapy
ES2214551T3 (es)	1995-11-02	2004-09-16	Schering Corporation	Terapia de infusion continua de citocinas a baja dosis.
US6172046B1 (en)	1997-09-21	2001-01-09	Schering Corporation	Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US6472373B1 (en)	1997-09-21	2002-10-29	Schering Corporation	Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
NZ508249A (en)	1998-06-08	2003-02-28	F	Use of PEG-IFN-alpha conjugates in association with ribavirin for the treatment of chronic hepatitis C
US6323180B1 (en)	1998-08-10	2001-11-27	Boehringer Ingelheim (Canada) Ltd	Hepatitis C inhibitor tri-peptides
US6824768B2 (en)	1998-12-18	2004-11-30	Schering Corporation	Ribavirin-pegylated interferon alfa induction HCV combination therapy
US6608027B1 (en)	1999-04-06	2003-08-19	Boehringer Ingelheim (Canada) Ltd	Macrocyclic peptides active against the hepatitis C virus
US6849254B1 (en)	1999-04-19	2005-02-01	Schering Corporation	HCV combination therapy
EP1313707B1 (en)	2000-08-09	2007-07-18	F. Hoffmann-La Roche Ag	Quinoline derivatives as anti-inflammation agents
EP2335700A1 (en)	2001-07-25	2011-06-22	Boehringer Ingelheim (Canada) Ltd.	Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US6867185B2 (en)	2001-12-20	2005-03-15	Bristol-Myers Squibb Company	Inhibitors of hepatitis C virus
US7119072B2 (en)	2002-01-30	2006-10-10	Boehringer Ingelheim (Canada) Ltd.	Macrocyclic peptides active against the hepatitis C virus
US20050075279A1 (en)	2002-10-25	2005-04-07	Boehringer Ingelheim International Gmbh	Macrocyclic peptides active against the hepatitis C virus
US7601709B2 (en)	2003-02-07	2009-10-13	Enanta Pharmaceuticals, Inc.	Macrocyclic hepatitis C serine protease inhibitors
CN1771257A (zh)	2003-04-10	2006-05-10	贝林格尔·英格海姆国际有限公司	通过钌络合物催化的易位反应制备大环化合物的方法
JP4231524B2 (ja)	2003-04-10	2009-03-04	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	大環状化合物の製造方法
ES2320771T3 (es)	2003-04-16	2009-05-28	Bristol-Myers Squibb Company	Inhibidores peptidicos de isoquinolina macrociclicos del virus de la hepatitis c.
NZ544076A (en) *	2003-05-21	2009-04-30	Boehringer Ingelheim Int	Hepatitis C inhibitor compounds
ZA200601181B (en)	2003-08-13	2007-04-25	Smith Howard J & Ass Pty Ltd	Method of treating viral infections
JP4704342B2 (ja)	2003-09-22	2011-06-15	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃ型肝炎ウイルスに対し活性な大環状ペプチド
AR045870A1 (es)	2003-10-11	2005-11-16	Vertex Pharma	Terapia de combinacion para la infeccion de virus de hepatitis c
US7491794B2 (en)	2003-10-14	2009-02-17	Intermune, Inc.	Macrocyclic compounds as inhibitors of viral replication
WO2005049065A2 (en)	2003-11-19	2005-06-02	Rigel Pharmaceuticals, Inc.	Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections
TWI368508B (en)	2004-02-20	2012-07-21	Boehringer Ingelheim Int	Viral polymerase inhibitors
US20050209135A1 (en)	2004-03-15	2005-09-22	Boehringer Ingelheim International Gmbh	Process for preparing macrocyclic compounds
BRPI0509467A (pt)	2004-03-30	2007-09-11	Intermune Inc	compostos macrocìclicos como inibidores de replicação viral
EP1753775B1 (en)	2004-05-25	2012-12-26	Boehringer Ingelheim International GmbH	Process for preparing acyclic hcv protease inhibitors
DE102004033312A1 (de)	2004-07-08	2006-01-26	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Kontinuierliches Metatheseverfahren mit Ruthenium-Katalysatoren
KR20070036175A (ko)	2004-07-14	2007-04-02	노파르티스 아게	Ｃ형 간염(ｈｃｖ)의 치료를 위한 시클로스포린과ｐｅｇ화된 인터페론의 조합 제제의 용도
EP1794179A1 (en)	2004-09-17	2007-06-13	Boehringer Ingelheim International Gmbh	Ring-closing metathesis process in supercritical fluid
US7375218B2 (en)	2004-09-17	2008-05-20	Boehringer Ingelheim International Gmbh	Process for preparing macrocyclic HCV protease inhibitors
PE20070211A1 (es)	2005-07-29	2007-05-12	Medivir Ab	Compuestos macrociclicos como inhibidores del virus de hepatitis c
JP2009526070A (ja)	2006-02-09	2009-07-16	シェーリングコーポレイション	Ｈｃｖプロテアーゼ阻害薬とｈｃｖポリメラーゼ阻害薬との組み合わせ、ならびにそれらに関連する処置の方法
WO2008070358A2 (en) *	2006-11-16	2008-06-12	Phenomix Corporation	N-cyclopropyl-hydroxyproline-based tripeptidic hepatitis c serine protease inhibitors containing an isoindole, pyrrolopyridine, pyrrolopyrimidine or pyrrolopyrazine heterocycle in the side chain
CA2691442C (en)	2007-06-29	2014-01-21	Gilead Sciences, Inc.	Antiviral compounds
SG182979A1 (en)	2007-06-29	2012-08-30	Gilead Sciences Inc	Antiviral compounds
WO2009014730A1 (en)	2007-07-26	2009-01-29	Idenix Pharmaceuticals, Inc.	Macrocyclic serine protease inhibitors
WO2009021121A2 (en)	2007-08-08	2009-02-12	Wyeth	Identification and characterization of hcv replicon variants with reduced susceptibility to a combination of polymerase and protease inhibitors, and methods related thereto
BRPI0908021A2 (pt)	2008-02-04	2015-07-21	Idenix Pharmaceuticals Inc	Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica
ES2474992T3 (es)	2008-09-16	2014-07-10	Boehringer Ingelheim International Gmbh	Formas cristalinas de un derivado de 2-tiazolil-4-quinolinil-oxi, un potente inhibidor de HCV
AU2009293493B2 (en)	2008-09-17	2014-09-18	Boehringer Ingelheim International Gmbh	Combination of HCV NS3 protease inhibitor with interferon and ribavirin
AR073603A1 (es)	2008-09-18	2010-11-17	Ortho Mcneil Janssen Pharm	Combinaciones sinergicas de un inhibidor macrociclico del vhc y un nucleosido
EA023433B1 (ru)	2009-07-07	2016-06-30	Бёрингер Ингельхайм Интернациональ Гмбх	Фармацевтическая композиция ингибитора протеазы вируса гепатита c
AU2010313497B2 (en)	2009-10-30	2013-08-01	Boehringer Ingelheim International Gmbh	Dosage regimens for HCV combination therapy comprising BI201335, interferon alpha and ribavirin
US8530497B2 (en)	2010-03-11	2013-09-10	Boehringer Ingelheim International Gmbh	Crystalline salts of a potent HCV inhibitor
MA34547B1 (fr)	2010-09-30	2013-09-02	Boehringer Ingelheim Int	Traitement d'association pour traiter une infection par le vhc

2009
- 2009-09-14 AU AU2009293493A patent/AU2009293493B2/en not_active Ceased
- 2009-09-14 EP EP09792492A patent/EP2337583A1/en not_active Withdrawn
- 2009-09-14 MY MYPI20111139 patent/MY152824A/en unknown
- 2009-09-14 CA CA2737376A patent/CA2737376A1/en not_active Abandoned
- 2009-09-14 CN CN2009801362929A patent/CN102159245B/zh not_active Expired - Fee Related
- 2009-09-14 PE PE2011000635A patent/PE20110343A1/es not_active Application Discontinuation
- 2009-09-14 WO PCT/US2009/056771 patent/WO2010033443A1/en not_active Ceased
- 2009-09-14 EA EA201100506A patent/EA019965B1/ru not_active IP Right Cessation
- 2009-09-14 UA UAA201104531A patent/UA103496C2/uk unknown
- 2009-09-14 NZ NZ591030A patent/NZ591030A/xx not_active IP Right Cessation
- 2009-09-14 JP JP2011527889A patent/JP5539363B2/ja not_active Expired - Fee Related
- 2009-09-14 BR BRPI0918653A patent/BRPI0918653A2/pt not_active IP Right Cessation
- 2009-09-14 MX MX2011002602A patent/MX2011002602A/es active IP Right Grant
- 2009-09-14 KR KR1020117005679A patent/KR20110054003A/ko not_active Ceased
- 2009-09-16 AR ARP090103556A patent/AR073516A1/es unknown
- 2009-09-16 TW TW098131293A patent/TWI454263B/zh not_active IP Right Cessation
- 2009-09-16 UY UY0001032124A patent/UY32124A/es not_active Application Discontinuation
- 2009-09-16 US US12/560,752 patent/US8399484B2/en active Active
2010
- 2010-12-20 ZA ZA2010/09151A patent/ZA201009151B/en unknown
- 2010-12-21 IL IL210152A patent/IL210152A0/en unknown
2011
- 2011-03-09 EC EC2011010877A patent/ECSP11010877A/es unknown
- 2011-03-14 MA MA33700A patent/MA32634B1/fr unknown
- 2011-03-16 CO CO11032826A patent/CO6351753A2/es not_active Application Discontinuation
- 2011-03-17 CL CL2011000571A patent/CL2011000571A1/es unknown

Also Published As

Publication number	Publication date
CO6351753A2 (es)	2011-12-20
WO2010033443A1 (en)	2010-03-25
EP2337583A1 (en)	2011-06-29
TW201016218A (en)	2010-05-01
EA019965B1 (ru)	2014-07-30
MY152824A (en)	2014-11-28
CN102159245A (zh)	2011-08-17
KR20110054003A (ko)	2011-05-24
US20100068182A1 (en)	2010-03-18
IL210152A0 (en)	2011-03-31
JP5539363B2 (ja)	2014-07-02
AU2009293493B2 (en)	2014-09-18
ZA201009151B (en)	2011-09-28
CA2737376A1 (en)	2010-03-25
EA201100506A1 (ru)	2011-10-31
TWI454263B (zh)	2014-10-01
CL2011000571A1 (es)	2011-07-29
PE20110343A1 (es)	2011-06-25
AR073516A1 (es)	2010-11-10
UY32124A (es)	2010-04-30
US8399484B2 (en)	2013-03-19
ECSP11010877A (es)	2011-04-29
MX2011002602A (es)	2011-04-07
NZ591030A (en)	2012-10-26
UA103496C2 (uk)	2013-10-25
AU2009293493A1 (en)	2010-03-25
CN102159245B (zh)	2013-07-24
JP2012502999A (ja)	2012-02-02
HK1156865A1 (en)	2012-06-22
MA32634B1 (fr)	2011-09-01

Legal Events

Date	Code	Title	Description
2016-09-20	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 7A ANUIDADE.
2017-01-17	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI0918653A2 (pt)	2015-12-01	combinação de inibidor de ns3 protese de hcv com interferon e ribavirina.
ATE501156T1 (de)	2011-03-15	Cyclopropyl-annelierte indolobenzazepine als hcv- ns5b-inhibitoren
EP2076278A4 (en)	2012-12-26	HCV NS3 proteinase inhibitor
EP2271345A4 (en)	2011-08-31	HCV NS3 proteinase inhibitor
ATE493428T1 (de)	2011-01-15	Hcv-nukleosidinhibitor
ECSP088157A (es)	2008-02-20	Inhibidores de proteasa ns3 del vhc
EP2079480A4 (en)	2011-06-15	HCV NS3 proteinase inhibitor
BRPI0923184A2 (pt)	2019-09-24	inibidores de hcv ns3 protease
EP2125870A4 (en)	2011-04-06	INHIBITORS OF HEPATITIS C NS3 PROTEASE
EP2083844A4 (en)	2010-12-01	INHIBITORS OF HCV NS3 PROTEASE
IL194434A0 (en)	2011-08-01	Hcv/hiv inhibitors and their uses
EP2079479A4 (en)	2010-12-22	Hcv ns3 protease inhibitors
CR8540A (es)	2009-01-16	Inhibidores de serina proteasa ns-3 del vhc
DK1924593T3 (da)	2010-01-25	HCV NS3-proteaseinhibitorer
ZA201104833B (en)	2012-03-28	Inhibitors of hcv ns5a
EP2373168A4 (en)	2012-08-01	HCV NS5A SHEMMER
IL198401A0 (en)	2010-02-17	Hcv ns3 protease inhibitors
CR10923A (es)	2009-11-09	Nuevos compuestos y sus efectos sobre el conductismo de la alimentacion
BRPI0716483A2 (pt)	2016-06-07	inibidores do vírus da hepatite c
BRPI0807087A2 (pt)	2014-06-10	Inibidores de hcv macrocíclicos substituídos de pirimidina
ES2355534T8 (es)	2011-05-09	Derivados de isoquinolina e isoquinolinona sustituidos con cicloalquilamina.
IL194777A0 (en)	2011-08-01	Hcv coreceptor and methods of use thereof
BRPI0919404A2 (pt)	2015-12-15	combinações sinergísticas de um inibidor macrocíclico do hcv e de um nucleosídeo
EP1994491A4 (en)	2010-11-17	INHIBITION OF FLAVIVIRUS BY RELATED SULTAMES AND COMPOUNDS
BRPI0721216A2 (pt)	2014-12-02	Composições de acetaminofen com efeitos colaterais minimizados e hepatotoxidez reduzida